Arthrex Acp Agreement

Croma still feels committed to high quality standards and Arthrex is known for its high quality products, support and reliability, collaboration has been the result. With products such as Arthrex ACP® dual injection, Arthrex has been one of the world`s leading biotech companies since 1981. The Arthrex ACP® double injection has been a success since 2007. Millions of Arthrex ACP® double injections have already been used by doctors around the world. The Arthrex ACP (Autologous Conditioned Plasma) system allows a rapid and efficient concentration of platelets and growth factors from the autologous blood, for use on the treatment site – The Arthrex ACP system is more affordable, easier to use and has a faster processing time compared to other traditional PRP devices you could try to access information for a product that is not allowed to be sold. Contact:CROMA-PHARMA GmbHStefanie HuhnDirection of communicationCromaline 2A-2100 LeobendorfPhone: `43 676 846868 190Mail: Home: Autologe Blood products have sparked growing interest in use in a number of therapies. The effects of plasma are supported by growth factors released by platelets. LEOBENDORF, Austria, 14.10.2019 /PRNewswire/ — Croma-Pharma GmbH (Croma) continues to harmonize its aesthetic portfolio. As part of the portfolio alignment, Croma proudly presents its own branded packaging design for the Arthrex ACP® dual injection system.

The new packaging design fits into the uniqueness of the Croma product range and its consistency with Croma, as there is a complete roof brand. Since April 2017, Croma-Pharma GmbH and Arthrex GmbH have been successfully collaborating with the Arthrex ACP® personalized cell therapy device as part of the Croma family of products. The Arthrex ACP® dual injection system for aesthetic applications is distributed by Croma exclusively in 9 European countries. White blood cells and red blood cells are NOT concentrated in the ACP About Croma-Pharma GmbH system Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company specializing in the development, manufacture and distribution of innovative products and services in aesthetic medicine, ophthalmology and orthopaedics. Croma currently operates 12 international distributors and markets its products in more than 70 countries. Within its global distribution network, Croma focuses on minimally invasive aesthetic medicine with its own branded products. In addition to a wide range of HA filling materials from its own production site, Croma markets PDO lifting wires, a Rich Plasma platelet system (PRP) and customized skin care technology in its key strategic markets.

This entry was posted in Uncategorized. Bookmark the permalink.

Comments are closed.